Pidilizumab (CT-011) is a humanized monoclonal antibody that modulates anti-tumor immune responses by targeting the PD-1 receptor and the Notch ligand DLL1. It enhances the activity of T cells and natural killer (NK) cells, demonstrating significant clinical potential in the study of hematologic malignancies, particularly follicular lymphoma.
CAS Nummer:
[1036730-42-3]
Target-Kategorie:
PD-1/PD-L1
T81461
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
